SLC5A2 and hepatocellular carcinoma: Recently, a large retrospective cohort study from Hong Kong compared the risk of new-onset HCC in patients with T2DM treated with SGLT2 inhibitors versus dipeptidyl peptidase-4 inhibitors (DPP4i).